- |||||||||| andecaliximab (GS-5745) / Gilead
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 13, 2015 P1, N=313, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=111 --> 313 | Trial primary completion date: Apr 2016 --> Feb 2018
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment change, Trial termination, Trial primary completion date, Metastases: Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc (clinicaltrials.gov) - Oct 7, 2015 P2, N=24, Terminated, Active, not recruiting --> Completed N=50 --> 24 | Recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Aug 2012; Due to poor Accrual
- |||||||||| ipatasertib (RG7440) / Roche
Enrollment open, Combination therapy, Metastases: Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 3, 2015 P1, N=120, Recruiting, Not yet recruiting --> Completed Active, not recruiting --> Recruiting
- |||||||||| Avastin (bevacizumab) / Roche, apitolisib (GDC-0980) / Roche
Trial completion, Trial primary completion date, Combination therapy, Metastases: GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 3, 2015 P1, N=43, Completed, Active, not recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Dec 2014
- |||||||||| dilpacimab (ABT-165) / AbbVie
Trial primary completion date, Metastases: A Study of ABT-165 in Subjects With Solid Tumors (clinicaltrials.gov) - Oct 1, 2015 P1, N=100, Recruiting, Trial primary completion date: Nov 2015 --> Nov 2016 Trial primary completion date: Jul 2015 --> Aug 2016
- |||||||||| TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial primary completion date: Phase II Trial Evaluating OS With Therasphere (clinicaltrials.gov) - Sep 24, 2015 P2, N=9, Active, not recruiting, Trial primary completion date: Oct 2017 --> Apr 2018 Trial primary completion date: Dec 2015 --> Apr 2016
- |||||||||| Erbitux (cetuximab) / Eli Lilly
Enrollment change, Trial termination, Trial primary completion date: Treatment Regimens for Patients With Resectable Liver Metastases (PANTER Study) (clinicaltrials.gov) - Sep 22, 2015 P=N/A, N=16, Terminated, Not yet recruiting --> Recruiting N=430 --> 16 | Active, not recruiting --> Terminated | Trial primary completion date: May 2015 --> Sep 2015; Recruitment difficulities
|